Legend Biotech Corporation (LEGN) is a Biotechnology company in the Healthcare sector, currently trading at $18.69. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is LEGN = $59 (+213.5% upside).
Valuation: LEGN trades at a trailing Price-to-Earnings (P/E) of -11.4 (S&P 500 average ~25).
Financials: revenue is $1.0B, +109.4%/yr average growth. Net income is $298M (loss), growing at -6.1%/yr. Net profit margin is -28.8% (negative). Gross margin is 60.3% (+16.2 pp trend).
Balance sheet: total debt is $414M against $1.0B equity (Debt-to-Equity (D/E) ratio 0.41, conservative). Current ratio is 1.96 (strong liquidity). Debt-to-assets is 23.9%. Total assets: $1.7B.
Analyst outlook: 16 / 19 analysts rate LEGN as buy (84%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 74/100 (Pass), Future 94/100 (Pass), Income 10/100 (Fail).
